ADC Therapeutics First Quarter Financial Results and Business Updates
ADC Therapeutics SA (ADCT) is a commercial-stage biotechnology company that creates novel antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors.
Today, ADC Therapeutics reported its first-quarter financial results and offered its business updates. It began with Chris Martin, Chief Executive Officer, stating, “We are off to an exciting start to the year with the recent accelerated FDA approval of ZYNLONTA™, bringing a new and differentiated treatment option to patients with relapsed or refractory diffuse large B-cell lymphoma. ZYNLONTA is approved for a broad population of r/r DLBCL patients, including DLBCL NOS, DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. This reflects the real-world population of patients enrolled in our LOTIS-2 pivotal trial including transplant eligible and ineligible patients, heavily pre-treated patients and patients with difficult-to-treat disease. In addition, we continue to advance our pipeline of next-generation ADCs for patients with difficult-to-treat hematologic and solid tumor cancers.”